APYXApyx Medical Corp

Nasdaq apyxmedical.com


$ 1.38 $ -0.05 (-3.55 %)    

Thursday, 28-Mar-2024 15:58:27 EDT
QQQ $ 443.93 $ -0.82 (-0.18 %)
DIA $ 397.72 $ 0.20 (0.05 %)
SPY $ 523.07 $ -0.10 (-0.02 %)
TLT $ 94.55 $ -0.08 (-0.08 %)
GLD $ 205.72 $ 2.62 (1.29 %)
$ 1.36
$ 1.35
$ 0.00 x 0
$ 0.00 x 0
$ 1.35 - $ 1.38
$ 1.21 - $ 7.97
121,168
na
47.09M
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-16-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-17-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
13 03-31-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-31-2020 12-31-2019 10-K
18 11-15-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-08-2019 03-31-2019 10-Q
21 03-14-2019 12-31-2018 10-K
22 11-02-2018 09-30-2018 10-Q
23 08-01-2018 06-30-2018 10-Q
24 05-15-2018 03-31-2018 10-Q
25 03-13-2018 12-31-2017 10-K
26 11-03-2017 09-30-2017 10-Q
27 08-03-2017 06-30-2017 10-Q
28 05-15-2017 03-31-2017 10-Q
29 03-10-2017 12-31-2016 10-K
30 10-27-2016 09-30-2016 10-Q
31 08-02-2016 06-30-2016 10-Q
32 05-11-2016 03-31-2016 10-Q
33 03-18-2016 12-31-2015 10-K
34 11-05-2015 09-30-2015 10-Q
35 08-07-2015 06-30-2015 10-Q
36 05-08-2015 03-31-2015 10-Q
37 02-27-2015 12-31-2014 10-K
38 11-10-2014 09-30-2014 10-Q
39 08-08-2014 06-30-2014 10-Q
40 05-15-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 crude-oil-moves-lower-accenture-shares-tumble-after-q2-results

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 300 points on Thursday. The Dow t...

 why-factset-research-shares-are-trading-lower-by-around-5-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-th...

 gold-gains-1-micron-posts-upbeat-results

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow tra...

 apyx-medical-expects-fy2024-sales-of-497m-529m-versus-consensus-of-6018m-with-net-loss-of-265m-243m

Total revenue guidance assumes: Advanced Energy revenue in the range of $41.6 million to $44.6 million, representing a de...

 apyx-medical-q4-gaap-eps-028-may-not-be-comparable-to-018-estimate-sales-1466m-miss-1485m-estimate

Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.18...

 earnings-scheduled-for-march-21-2024

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...

 apyx-medical-reports-preliminary-fy23-revenues-of-519m-523m-up-17-18-yy-versus-consensus-of-5325m

Advanced Energy revenue in a range of approximately $43.1 to $43.5 million, representing growth of 17% to 18% year-over-year....

 apyx-medical-reports-preliminary-q4-revenues-of-142m-146m-up-13-16-yy-versus-consensus-of-1558m

Advanced Energy revenue in a range of approximately $11.9 to $12.3 million, representing growth of 12% to 16% year-over-year....

 insiders-buying-apyx-medical-and-3-other-stocks-under-3

The Dow Jones closed higher by over 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confiden...

 stephens--co-maintains-overweight-on-apyx-medical-lowers-price-target-to-5

Stephens & Co. analyst George Sellers maintains Apyx Medical (NASDAQ:APYX) with a Overweight and lowers the price target...

 apyx-medical-forecasts-fy23-revenues-of-53m-54m-compared-to-prior-guidance-of-59m-62m-and-consensus-of-5968m

Total revenue in the range of , representing growth of approximately 19% to 21% year-over-year, compared to total revenue of $4...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION